GSK's Shingrix Approved in China for Prevention of Shingles in Adults Aged 18 and Over Who are at Increased Risk Due to Immunodeficiency or Immunosuppression
October 15, 2025
October 15, 2025
LONDON, England, Oct. 15 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Oct. 14, 2025:
* * *
GSK's Shingrix approved in China for prevention of shingles in adults aged 18 and over who are at increased risk due to immunodeficiency or immunosuppression
- Shingrix (GSK's Recombinant Zoster Vaccine or RZV) is the first and only vaccine approved in this population in China
- Approval ad . . .
* * *
GSK's Shingrix approved in China for prevention of shingles in adults aged 18 and over who are at increased risk due to immunodeficiency or immunosuppression
- Shingrix (GSK's Recombinant Zoster Vaccine or RZV) is the first and only vaccine approved in this population in China
- Approval ad . . .